Suven Life Sciences, a Hyderabad-based drug company, announced that it has received patents from the United States and New Zealand patent offices.
The valuable patents are for what are referred to as “new chemical entities” (NCEs) which they developed for the treatment of cognitive impairment which is associated with illnesses of the nervous system, specifically neuro-degenerative disorders.
The patents will be in effect until 2030 for one and 2031 for the other.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,”said Venkat Jasti, CEO of Suven.
These newly granted patents bring the total patents Suven has secured up to 20 from the US and 23 from New Zealand.
“These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II,” Suven said.